You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康希諾生物-B連漲10日,今年以來股價漲幅300%
uSMART友信智投 05-20 13:40

uSMART友信智投5月20日消息,週三港股,"全球進展最快新冠疫苗股"康希諾生物-B連續10日股價上揚,接連創新高,截至北京時間11時41分,康希諾生物-B漲5.31%,報238港元,今年以來,康希諾生物-B已累漲303.73%

圖片來源:uSMART友信智投

隔夜,"美國新冠疫苗明星股"Moderna的試驗結果遭質疑,STAT News在一則報導中質疑Moderna週一宣佈的疫苗試驗結果的有效性,消息發出後,美國三大股指跌至盤中低點。Moderna在報導發佈後大幅下挫,收盤急挫10.41%。

圖片來源:uSMART友信智投

對於當前的疫情,疫苗就像"救世主",相關概念在二級市場上炒作不斷。在新冠疫苗的賽道上,二級市場投資者是在押注產品研發的進展及結果,康希諾生物-B近期臨床資料揭盲,資料結果將主導康希諾生物-B股價的下一步走勢

什麼是臨床試驗的盲底?

亂數、產生亂數的參數及試驗用藥物編碼統稱為雙盲臨床試驗的盲底。盲底是密封的,一式兩份,由申辦方、組長單位的藥物臨床試驗機構保存。

盲底揭盲有何規定?

1、雙盲試驗,當試驗組與對照組按1:1設計時,採用兩次揭盲法。

2、兩次揭盲都由保存盲底的有關人員(申辦方、組長單位主要研究者)執行。

3、資料檔案經過盲態審核並認定可靠無誤後將被鎖定,進行第一次揭盲,此次揭盲只列出每個病例所屬的組別(如A組或B組)。

4、當統計分析結束後進行第二次揭盲,以明確哪一個為試驗組或對照組。

關於康希諾生物

康希諾生物股份公司(簡稱:康希諾生物,股票代碼6185.HK),2009年成立于中國天津,致力於為中國及全球公共衛生研發、生產和商業化創新疫苗。公司現有四個創新疫苗平臺技術,包括腺病毒載體疫苗技術、結合技術、蛋白設計與重組技術、製劑技術。目前,公司已建立覆蓋13種傳染病的16種疫苗的強大研發管線,其中包括2017年獲得批准的全球創新重組埃博拉病毒病疫苗以及目前在研的重組新型冠狀病毒疫苗。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account